Global Noninvasive Prenatal Testing (NIPT) Market by Diagnostic Tests, Geography, Trends and Forecast to 2021

Prenatal diagnosis or prenatal screening refers to testing for diseases or conditions in a fetus or embryo before it is born. Non-invasive prenatal testing (NIPT) test can detect birth defects such as neural tube defects, Down syndrome, chromosome abnormalities, genetic disorders and other conditions, such as spina bifida, cleft palate, Tay–Sachs disease, sickle cell anemia, thalassemia, cystic fibrosis, Muscular dystrophy, and fragile X syndrome. NIPT is used for screening pregnant women at high risk of developing fetal chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome (monosomy X) along with fetal sex determination. Amniocentesis, chorionic villus sampling (CVS), maternal serum screening, and nuchal translucency (NT) scan have been the primary diagnostic and screening methods for chromosomal abnormalities. NIPT is an innovative way of screening pregnancies for fetal chromosomal aneuploidies by analyzing fetal cell-free DNA circulating in maternal blood.

Browse Noninvasive Prenatal Testing (NIPT) Market by NIPT-Specific Test Types (BambniTest, Harmony, informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, verify, VisibiliT) and Forecast 2017-2021 report at https://www.ihealthcareanalyst.com/report/non-invasive-prenatal-testing-market/

The global noninvasive prenatal testing market report estimates the market size (Revenue USD million - 2014 to 2021) for market segmentation based on NIPT-specific test types (BambniTest, Harmony, informaSeq, MaterniT21 PLUS, NIFTY, Panorama, PrenaTest, verify, VisibiliT, etc.), and forecasts growth trends (CAGR% - 2017 to 2021).

The global noninvasive prenatal testing market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global noninvasive prenatal testing market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global noninvasive prenatal testing market and included in this report are Ariosa Diagnostics, Berry Genomics, BGI Diagnostics, Illumina, Inc., LifeCodexx AG, LabCorp, Natera, Inc., and Sequenom, Inc.

1. Diagnostic Test Type
1.1. BambniTest
1.2. Harmony Test
1.3. informaSeq Test
1.4. MaterniT21 PLUS
1.5. NIFTY Test
1.6. Panorama Test
1.7. PrenaTest
1.8. Verify Test
1.9. VisibiliT Test
1.10. Others

2. Company Profiles
2.1. Ariosa Diagnostics, Inc.
2.2. Berry Genomics Co., Ltd.
2.3. BGI Diagnostics
2.4. Illumina, Inc.
2.5. Laboratory Corporation of America Holdings (LabCorp)
2.6. LifeCodexx AG
2.7. Natera, Inc.
2.8. Sequenom, Inc.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/non-invasive-prenatal-testing-market/

iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare IT, healthcare services, medical devices, medical equipment, and pharmaceuticals.

In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com

This release was published on openPR.